CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol

oleh: Farzaneh Ghazavi, Emmanuelle Clappier, Tim Lammens, Stefan Suciu, Aurélie Caye, Samira Zegrari, Marleen Bakkus, Nathalie Grardel, Yves Benoit, Yves Bertrand, Odile Minckes, Vitor Costa, Alina Ferster, Françoise Mazingue, Geneviève Plat, Emmanuel Plouvier, Marilyne Poirée, Anne Uyttebroeck, Jutte van der Werff-ten Bosch, Karima Yakouben, Hetty Helsmoortel, Magali Meul, Nadine Van Roy, Jan Philippé, Frank Speleman, Hélène Cavé, Pieter Van Vlierberghe, Barbara De Moerloose

Format: Article
Diterbitkan: Ferrata Storti Foundation 2015-10-01

Deskripsi

DNA copy number analysis has been instrumental for the identification of genetic alterations in B-cell precursor acute lymphoblastic leukemia. Notably, some of these genetic defects have been associated with poor treatment outcome and might be relevant for future risk stratification. In this study, we characterized recurrent deletions of CD200 and BTLA genes, mediated by recombination-activating genes, and used breakpoint-specific polymerase chain reaction assay to screen a cohort of 1154 cases of B-cell precursor acute lymphoblastic leukemia uniformly treated according to the EORTC-CLG 58951 protocol. CD200/BTLA deletions were identified in 56 of the patients (4.8%) and were associated with an inferior 8-year event free survival in this treatment protocol [70.2% ± 1.2% for patients with deletions versus 83.5% ± 6.4% for non-deleted cases (hazard ratio 2.02; 95% confidence interval 1.23–3.32; P=0.005)]. Genetically, CD200/BTLA deletions were strongly associated with ETV6-RUNX1-positive leukemias (P